Analysis of disease activity categories in chronic spontaneous/idiopathic urticariaDonald E. Stull, Clive Grattan, S Khalil et al.|British Journal of Dermatology|2017Cited by 82
Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous UrticariaAlan Brennan, Doreen McBride, Donald E. Stull et al.|PharmacoEconomics|2016Cited by 40
Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studiesAna M. Giménez‐Arnau, Thomas Murphy, Sheldon L. Spector et al.|Clinical and Translational Allergy|2016Cited by 34
Weekly Urticaria Activity Score (UAS7) and Dermatology Life Quality Index (DLQI) in Validation of Chronic Spontaneous/Idiopathic Urticaria (CSU/CIU) Health StatesSam Khalil, Donald E. Stull, Doreen McBride et al.|Journal of Allergy and Clinical Immunology|2015Cited by 20
Assessing Changes in Chronic Spontaneous/Idiopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth ModelingDonald E. Stull, Maria‐Magdalena Balp, Doreen McBride et al.|Advances in Therapy|2016Cited by 19